Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $379M | $1.29B | $1.40B | $1.27B | $1.27B | $1.32B | $2.28B | $2.26B | $2.38B | $2.23B |
| Revenue growth | — | 240.7% | 8.3% | -9.6% | 0.4% | 3.6% | 73.2% | -0.9% | 5.4% | -6.3% |
| Gross profit | $201M | $426M | $570M | $472M | $461M | $491M | $698M | $740M | $825M | $822M |
| Gross margin | 53.1% | 33.0% | 40.7% | 37.3% | 36.3% | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% |
| Operating income | $82.9M | -$13.3M | $29.8M | $107M | $98.2M | $123M | -$42.9M | $22.8M | $43.0M | $42.8M |
| Operating margin | 21.9% | -1.0% | 2.1% | 8.5% | 7.7% | 9.4% | -1.9% | 1.0% | 1.8% | 1.9% |
| Net income | $63.1M | $68.6M | $28.8M | $101M | $86.9M | $103M | -$74.3M | -$29.7M | -$118M | $732K |
| Net margin | 16.6% | 5.3% | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
| EPS (diluted) | $3.66 | $3.29 | $1.33 | $4.69 | $4.02 | $4.74 | -$3.11 | -$1.23 | -$4.83 | $0.03 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $89.9M | $154M | $160M | $102M | $223M | $268M | -$62.1M | $166M | $204M | $180M |
| Capital expenditures | $23.4M | $74.5M | $92.7M | $97.3M | $92.0M | $68.5M | $90.3M | $83.9M | $79.4M | $88.0M |
| Free cash flow | $66.6M | $79.9M | $67.5M | $4.61M | $131M | $199M | -$152M | $82.3M | $125M | $91.8M |
| Share buybacks | $17.2M | $4.06M | $6.25M | $18.6M | $12.9M | $8.34M | $10.9M | $9.35M | $12.0M | $8.77M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $445M | $290M | $345M | $269M | $396M | $553M | $209M | $254M | $309M | $308M |
| Total assets | $705M | $1.50B | $1.59B | $1.69B | $1.76B | $1.88B | $4.52B | $4.38B | $4.20B | $4.05B |
| Long-term debt | — | — | — | — | — | — | $1.62B | $1.58B | $1.53B | $1.27B |
| Shareholders' equity | $660M | $1.20B | $1.26B | $1.38B | $1.50B | $1.62B | $2.09B | $2.12B | $1.97B | $2.12B |
| Retained earnings | $517M | $586M | $621M | $722M | $809M | $912M | $838M | $808M | $690M | $691M |
| Shares (wtd avg diluted) | 17.3M | 20.9M | 21.6M | 21.5M | 21.6M | 21.8M | 23.9M | 24.1M | 24.4M | 24.9M |
Every figure is extracted from ICU MEDICAL INC/DE’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.